DNTH Dianthus Pharma: רווח למניה בשנים עשר החודשים האחרונים

Dianthus Therapeutics develops complement inhibitors to combat autoimmune pathologies, focusing on the drug DNTH103. This GURU.Markets chart illustrating the trend of rolling annual earnings per share reflects the current state of the business, where -3.97 captures the value of this parameter. The company attracts talented biologists through a lack of bureaucracy and growth potential, although high R&D expenses create a cash deficit.
פילוחים אנליטיים ודוחות נתונים של חברת Dianthus Pharma (DNTH)

For Dianthus Therapeutics (DNTH), whose market capitalization depends on the commercialization of monoclonal antibodies against neuromyelitis, earnings per share reflect the efficiency of transforming innovations into actual revenue. Analyzing the TTM earnings per share chart, an investor sees the net financial result for the year distributed per share, which allows for an assessment of the business's fundamental value without accounting distortions.